CRVS – corvus pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
3/26
12:07 pm
crvs
Low
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc..
3/26
08:19 am
crvs
High
Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.00 price target on the stock.
3/25
04:01 pm
crvs
High
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results
3/20
08:00 am
crvs
Medium
Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma
3/19
04:01 pm
crvs
Medium
Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference
3/25/2025
04:01 pm
CRVS
-14.8%
MISS
11/12/2024
04:01 pm
CRVS
2.1%
MISS
8/6/2024
04:01 pm
CRVS
4.4%
BEAT
5/6/2024
04:01 pm
CRVS
-12.0%
IN-LINE
3/26
12:59 pm
Maintains
Outperform
Outperform
Oppenheimer
Low
-0.9%
3/26
12:59 pm
Maintains
Outperform
Outperform
Oppenheimer
Low
-0.9%
3/26
12:07 pm
Reiterates
Outperform
Outperform
Oppenheimer Holdings Inc.
Low
0.4%
3/26
08:19 am
Reiterates
Buy
Buy
HC Wainwright
High
-18.3%
1/14
08:02 am
Reiterates
Buy
Buy
HC Wainwright
Low
-1.9%
3/25
04:07 pm
crvs
High
Form 10-K Corvus Pharmaceuticals, For: Dec 31
3/25
04:01 pm
crvs
High
Form 8-K Corvus Pharmaceuticals, For: Mar 25
2/14
01:54 pm
crvs
Low
Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: SAMLYN CAPITAL, LLC
2/13
04:30 pm
crvs
Low
Form SCHEDULE 13G/A Corvus Pharmaceuticals, Filed by: MILLER RICHARD A MD
1/13
07:30 am
crvs
Low
Form 8-K Corvus Pharmaceuticals, For: Jan 13
Show more
Top News Gainers
7/2 Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC 25.5%
7/1 Form 4 Corvus Pharmaceuticals, For: Jun 27 Filed by: ORBIMED ADVISORS LLC 21.0%
8/8 Form 4 Corvus Pharmaceuticals, For: Aug 06 Filed by: MILLER RICHARD A MD 20.7%
11/4 Corvus Pharmaceuticals to Webcast Investor & Analyst Event on November 8, 2019 12.4%
3/20 Form EFFECT Corvus Pharmaceuticals, 12.3%
12/16 Form 4 Corvus Pharmaceuticals, For: Dec 12 Filed by: Hunt Daniel W. 10.6%
11/14 Form 4 Corvus Pharmaceuticals, For: Nov 12 Filed by: MILLER RICHARD A MD 9.9%
4/15 Form DEF 14A Corvus Pharmaceuticals, For: Jun 09 7.3%
10/17 Corvus Pharmaceuticals to Provide Business Update and Report Third Quarter 2019 Financial Results on October 29, 2019 6.7%
5/9 Q1/2019 3/31/2019 EPS -0.400 ZacksConsensus -0.400 ActVsEst 0.000 - In-Line 6.1%
Top News Decliners
4/30 Form 10-Q Corvus Pharmaceuticals, For: Mar 31 -13.7%
3/5 Q4/2019 12/31/2019 EPS -0.380 ZacksConsensus -0.330 ActVsEst (0.050) - Miss -12.5%
3/20 Form 424B5 Corvus Pharmaceuticals, -11.4%
7/15 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -10.3%
11/12 Form 8-K Corvus Pharmaceuticals, For: Nov 08 -9.3%
2/13 Corvus Pharmaceuticals Presents Updated Clinical Data from its Phase 1b/2 Clinical Trial of Ciforadenant at the 2020 American Society of Clinical Oncology’s Genitourinary Cancers Symposium -9.3%
8/4 Corvus Pharmaceuticals, Inc. (CRVS) CEO Richard Miller on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -9.2%
11/8 Corvus Pharmaceuticals Presents Updated Data from CPI-006 Phase 1/1b Clinical Trial at 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting -9.2%
12/31 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -8.3%
9/12 Corvus Pharmaceuticals Inc (NASDAQ: CRVS) had its "buy" rating re-affirmed by analysts at Mizuho. They now have a $7.00 price target on the stock. -8.2%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3